Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder

The authors of this helpful paper write: "Depression is common in patients with cancer and associated with lower treatment adherence, reduced quality of life, and limited response to antidepressants and psychotherapy. We conducted a phase 2 trial to study a single dose of psilocybin administered in a group therapy setting with one-to-one therapist-to-participant psychological support to patients with curable and noncurable cancer and major depressive disorder. Findings of the study showed safety (no treatment-related serious adverse events or suicidality) with psilocybin and suggested efficacy, with a significant reduction in depression severity scores from baseline to posttreatment. Further investigation is warranted." There is also the companion qualitative study Acceptability of psilocybin-assisted group therapy in patients with cancer and major depressive disorder: Qualitative analysis and the linked editorial Innovations in group-based psilocybin-assisted therapy of major depression in patients with cancer.

For more psychedelic news and research, visit the psychedelic health professional network homepage.

Previous
Previous

The relation between naturalistic use of psychedelics and perception of emotional stimuli: An event-related potential study comparing non-users and experienced users of classic psychedelics

Next
Next

Must psilocybin always “Assist psychotherapy”?